Given that patients with MGUS have reduced survival compared with the general population, likely due to their inherently higher burden of comorbidities, these findings suggest that the cardiac and renal benefits of GLP-1 RAs extend to patients with MGUS and diabetes. This evidence concerns the gene GCG and diabetes mellitus.